Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: PR Newswire
Showing New Indication for Nu.Q® NETs HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference in Malta on 5th February. The session entitled "Empowering Precision-medicine approach through NETs Plasma Biomarker-driven personalized treatment" will be presented by Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, at the 4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece.Professor Evangelos J. Giamarellos-Bourboulis commented:"The scientific program at the EHSF conference this year provides a focus on genetics and updates on basic research, including the diagnosis and management of Hidradenitis Suppurativa (HS)."I am delighted to present data from the recently released clinical study demonstrating the use of Volition's Nu.Q® NETs assay in patient ma
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer AssaysPR Newswire
- Volition Announces Data to Support Use of Nu.Q® NETs in New IndicationPR Newswire
- VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.MarketBeat
- Volition Continues to Extend Access to Nu.Q® Vet Cancer TestPR Newswire
- Volition Sponsors Symposium at Veterinary Meeting and ExpoPR Newswire
VNRX
Earnings
- 11/13/25 - Miss
VNRX
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- VNRX's page on the SEC website